Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis.

By M. Yokoyama, H. Origasa, M. Matsuzaki, Yuji Matsuzawa, Y. Saito, Y. Ishikawa, S. Oikawa, J. Sasaki, H. Hishida, H. Itakura and 6 more. The Lancet, 2007

2,495 citations recorded by the source corpus.

Subfields: Biochemistry, Nutrition and Dietetics, Surgery

View Paper: https://www.semanticscholar.org/paper/2d1bef2cf54ff85ccfd6e7f461af1804f679f05d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Nutrition and Dietetics

1. Shaker A. Mousa
2. S. Grundy

In Surgery

1. S. Gidding
2. S. Grundy
3. R. Eckel
4. R. Bilous

Citations in the corpus

• Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. (2011, background): “This trial found an additional 20% reduction in CHD events with eicosapentaenoic acid (EPA) 1800 mg in statin treated hypercholesterolemic patients with and without CVD.(65) EPA did not influence LDL cholesterol level in this population without significant HDL cholesterol (58 mg/dL) or triglyceride ”